StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note issued to investors on Thursday morning. The firm issued a sell rating on the stock. Separately, Roth Mkm reaffirmed a buy rating and set a $40.00 price target on shares of Bio-Path in a research report on Thursday, April 18th. […]
StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a report published on Wednesday. The firm issued a sell rating on the stock. Separately, Roth Mkm reissued a buy rating and set a $40.00 price objective on shares of Bio-Path in a research report on Thursday, April 18th. Get Our Latest Research […]
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its.
Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 63,400 shares, an increase of 284.2% from the February 29th total of 16,500 shares. Approximately 9.6% of the shares of the company are short sold. Based […]
Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 63,400 shares, an increase of 284.2% from the February 29th total of 16,500 shares. Currently, 9.6% of the shares of the company are short sold. Based […]